Noninvasive diagnostic system developer RSP Systems (Odense, Denmark) has completed second closing of its Series B round. This closing brings in an additional €3.85 million, bringing the round to €10.35 million in total. The proceeds will be used to fund clinical trials and to prepare for regulatory approval and market launch of its Raman spectroscopy-based glucose monitor in Europe.
Existing and new investors have contributed to the company's Series B round. Among these new investors is Trumpf Venture, the corporate venture arm of machine tools and lasers manufacturer Trumpf (Ditzingen, Germany).
For more information, please visit www.rspsystems.com.